10 things to know about Titan Spine

Surface Technology

Titan Spine is a medical device manufacturer focused on titanium implants with a proprietary roughened implant surface treatment for spinal fusion.

1. Former orthopedic spine surgeon Peter Ullrich, MD, and Kevin Gemas co-founded Titan Spine to meet the need for interbody fusion space for cages designed to enhance fixation, preserve vertebral body integrity and promote fusion.


2. Mequon, Wis.-based Titan Spine distributes its Endoskeleton titanium interbody cage device platform in the U.S. and Europe.


3. Titan Spine's proprietary nano surface technology relies on titanium, a material used in orthopedics because of its high strength, low weight and ability to promote osteointegration for lasting and firm fixation. Here is more information on Titan Spine's nano surface technology.


4. In 2016, CMS created a new technology ICD-10 code for interbody fusion procedures using nano-textured interbody fusion devices, allowing CMS to collect and analyze outcome data for users of the code. nanoLOCK is currently the only device with access to use the code.


5. At mid-year 2017, Titan Spine reported a 49 percent year-over-year growth rate. nanoLOCK sales volume rose 42 percent since the end of the first quarter 2017, and 150 surgeons used the nanoLOCK in 98 hospitals, according to the company. Surgeons have performed 2,500 nanoLOCK implantations since its 2016 launch and implanted more than 50,000 Endoskeleton interbody fusion devices.


6. Titan Spine has been growing at over 40 percent per year for over 10 years. It now has about 110 employees.


7. Titan Spine raised an indefinite series B equity fund for early investors that launched in June 2012 and totaled $202,262, and a series B round launched in August 2016 now totals $1.8 million.


8. The company raised another $7.5 million for its series D funding round, which is now at $15 million. The funding came entirely from Texas private equity firm Southlake Equity Group, which initially invested $7.5 million in June 2016 and deployed another $7.5 million in a second installment in February 2017. The investment gave Southlake a minority ownership stake in Titan Spine.


9. In 2017, Titan Spine entered the Australian market when spine surgeon Dr. Richard Laherty successfully performed the first two ALIF cases using Titan Spine's proprietary Endoskeleton interbody fusion devices and surface technology in October.


10. Titan Spine's Endoskeleton device offerings are indicated for use in skeletally mature patients with degenerative disc disease.


More articles on surface technology:

3 observations on spine implant technology from Dr. Christian Zimmerman

CTL Medical receives FDA clearance for ACIF cage with TiCro technology: 4 key notes

3-D titanium printing, customizable implants are the biggest innovation in implant material + 2 other trends from Dr. Kern Singh

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers